Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
Tanja Pejović, Katherine Fitch, Gordon B. Mills
Abstract
PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.
Topics & Concepts
Ovarian cancerPoly ADP ribose polymeraseMedicineSerous ovarian cancerDiseasePARP inhibitorCancer researchOncologyBiomarkerCancerPolymeraseSerous fluidInternal medicineBiologyGeneticsGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentDNA Repair Mechanisms